Menopause Practice Questions

Q: Regarding vasomotor symptoms seen with menopause, all are true except?

Hot flush affects typically trunk and limbs.. **Explanation:** Vasomotor symptoms (VMS), primarily manifesting as **hot flushes**, are the hallmark of the perimenopausal transition. **Why Option C is the Correct Answer (The False Statement):** A hot flush typically begins as a sudden sensation of intense heat in the **face, neck, and upper chest (the "blush area")**, often accompanied by profuse sweating and palpitations. It does **not** typically involve the limbs. The sensation is caused by peripheral vasodilation to dissipate heat, followed by a compensatory drop in core body temperature. **Analysis of Other Options:** * **Option A:** VMS is indeed the **most common** and earliest symptom of menopause, affecting the majority of women. * **Option B:** The pathophysiology involves a "narrowing of the thermoregulatory window" in the hypothalamus. The withdrawal of estrogen leads to a decrease in endorphins and an increase in norepinephrine and serotonin, which disrupts the body's thermostat. * **Option D:** Approximately **70-80%** of women experience these symptoms during the menopausal transition, though the severity and duration vary significantly. **High-Yield NEET-PG Pearls:** * **Duration:** Hot flushes usually last for 1–5 minutes. While they typically subside within 1–2 years, about 10–15% of women may experience them for over 10 years. * **Night Sweats:** When VMS occurs during sleep, it is termed "night sweats," which often leads to insomnia and "brain fog." * **Treatment Gold Standard:** **Hormone Replacement Therapy (HRT)** is the most effective treatment for VMS. * **Non-Hormonal Alternatives:** SSRIs (Paroxetine), SNRIs (Venlafaxine), and Gabapentin are used for patients where HRT is contraindicated (e.g., history of breast cancer).

Q: Which of the following is NOT true about the menopausal transition?

Increase in inhibin B. **Explanation:** The menopausal transition is characterized by the depletion of the ovarian follicle pool. To understand the hormonal changes, one must remember the feedback loop between the ovaries and the pituitary gland. **Why Option D is the Correct Answer:** Inhibin B is produced by the granulosa cells of the developing antral follicles. As the number of viable follicles declines during the perimenopausal period, the production of **Inhibin B decreases**. Inhibin B normally exerts negative feedback on the anterior pituitary to suppress FSH. Therefore, a **decrease** (not an increase) in Inhibin B is one of the earliest markers of reproductive aging. **Analysis of Incorrect Options:** * **A. Increase in FSH:** This is the hallmark of menopause. As Inhibin B and Estrogen levels fall, the negative feedback is removed, leading to a compensatory rise in FSH (typically >40 IU/L in menopause). * **B. Decrease in Estrogen:** With the exhaustion of follicles, the primary source of estradiol ($E_2$) disappears. While peripheral conversion of androgens to estrone ($E_1$) continues in adipose tissue, overall estrogen levels significantly decline. * **C. Decrease in AMH:** Anti-Müllerian Hormone (AMH) is produced by pre-antral and small antral follicles. It is the most sensitive marker of ovarian reserve and begins to decline years before the actual menopause. **NEET-PG High-Yield Pearls:** 1. **Earliest hormonal change:** Decrease in Inhibin B. 2. **Earliest clinical sign:** Shortening of the follicular phase (leading to shorter menstrual cycles). 3. **Most sensitive marker of ovarian reserve:** AMH (levels 40 IU/L is diagnostic). 5. **Predominant Estrogen post-menopause:** Estrone ($E_1$), converted in peripheral fat.

Q: What is an absolute contraindication to hormone replacement therapy?

Otosclerosis. **Explanation:** The correct answer is **Otosclerosis**. In the context of Hormone Replacement Therapy (HRT), it is crucial to distinguish between indications, relative contraindications, and absolute contraindications. **Why Otosclerosis is the Correct Answer:** Otosclerosis is a condition characterized by abnormal bone remodeling in the middle ear. Estrogen is known to accelerate the progression of otosclerotic lesions, potentially leading to rapid and irreversible conductive hearing loss. Therefore, it is considered an **absolute contraindication** to HRT. **Analysis of Incorrect Options:** * **Osteoporosis:** This is a primary **indication** for HRT. Estrogen inhibits osteoclast activity, reducing bone resorption and the risk of fractures in postmenopausal women. * **Colon Cancer:** HRT (specifically combined estrogen-progestogen therapy) is actually associated with a **decreased risk** of colorectal cancer. It is not a contraindication. * **Premature Menopause:** This is a strong **indication** for HRT. Women with premature ovarian insufficiency (POI) require HRT until at least the average age of natural menopause (approx. 51 years) to prevent cardiovascular disease and osteoporosis. **High-Yield Clinical Pearls for NEET-PG:** * **Absolute Contraindications to HRT:** Undiagnosed abnormal vaginal bleeding, known or suspected pregnancy, active thromboembolic disease (DVT/PE), active liver disease, and estrogen-dependent tumors (e.g., Breast or Endometrial cancer). * **Otosclerosis & Pregnancy:** Hearing loss in otosclerosis often worsens during pregnancy due to high endogenous estrogen levels. * **Gold Standard for Vasomotor Symptoms:** HRT remains the most effective treatment for "hot flashes" and "night sweats." * **Window of Opportunity:** HRT is safest when started within 10 years of menopause or before age 60.

Q: All of the following agents are used in the treatment of hot flashes, EXCEPT?

Tamoxifen. **Explanation:** The management of vasomotor symptoms (hot flashes) in menopause involves both hormonal and non-hormonal therapies. **Why Tamoxifen is the Correct Answer:** **Tamoxifen** is a Selective Estrogen Receptor Modulator (SERM) used primarily in breast cancer treatment. It acts as an estrogen antagonist in the breast but as an agonist in other tissues. Crucially, Tamoxifen is well-known to **induce or worsen hot flashes** as a side effect rather than treating them. In contrast, Estrogen Replacement Therapy (ERT) is the gold standard for treating hot flashes, but Tamoxifen's anti-estrogenic effect on the hypothalamus triggers thermoregulatory instability. **Analysis of Other Options:** * **Venlafaxine (Option B):** A Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). It is a highly effective non-hormonal treatment for hot flashes, especially in breast cancer survivors who cannot take estrogen. * **Gabapentin (Option C):** An anti-convulsant that has been shown to significantly reduce the frequency and severity of hot flashes by modulating calcium channels in the hypothalamus. * **Paroxetine (Option D):** An SSRI. Low-dose Paroxetine is the only non-hormonal medication specifically **FDA-approved** for the treatment of moderate-to-severe vasomotor symptoms. **Clinical Pearls for NEET-PG:** * **Gold Standard Treatment:** Estrogen (HRT) is the most effective treatment for vasomotor symptoms. * **FDA-Approved Non-Hormonal:** Low-dose Paroxetine (7.5 mg). * **Clonidine:** A centrally acting alpha-2 agonist is also used but is generally considered second-line due to side effects like hypotension and dry mouth. * **Tibolone:** A synthetic steroid with estrogenic, progestogenic, and androgenic properties that also treats hot flashes.

Q: Which of the following is NOT a contraindication for estrogen therapy?

Hypertension. **Explanation:** The core principle in prescribing Estrogen Therapy (ET) or Hormone Replacement Therapy (HRT) is identifying **estrogen-dependent pathologies** and **pro-coagulant risks**. **Why Hypertension is the Correct Answer:** Controlled hypertension is a **relative precaution**, not an absolute contraindication for estrogen therapy. While oral estrogens can slightly increase blood pressure via the stimulation of hepatic renin substrate (angiotensinogen), most women with well-controlled BP can safely use ET. In such cases, **transdermal patches** are preferred as they bypass the first-pass hepatic metabolism, minimizing the effect on the Renin-Angiotensin-Aldosterone System (RAAS). **Why the Other Options are Incorrect:** * **Breast Cancer:** Estrogen promotes the proliferation of mammary epithelium. A history of breast cancer is an **absolute contraindication** as it may stimulate the recurrence of micrometastases. * **Uterine (Endometrial) Cancer:** Estrogen causes endometrial hyperplasia. In women with an intact uterus, "unopposed estrogen" significantly increases the risk of endometrial carcinoma. A history of this malignancy precludes ET. * **Previous Thromboembolism:** Estrogen increases the synthesis of clotting factors (II, VII, IX, X) and decreases Antithrombin III. A history of DVT or Pulmonary Embolism is a major contraindication due to the high risk of recurrent thrombotic events. **NEET-PG High-Yield Pearls:** * **Absolute Contraindications to HRT:** Undiagnosed abnormal vaginal bleeding, known/suspected pregnancy, active liver disease, and hormone-dependent tumors. * **Route Matters:** Transdermal estrogen does not increase the risk of venous thromboembolism (VTE) to the same extent as oral estrogen. * **The "Window of Opportunity":** HRT is most beneficial and safest when started within 10 years of menopause or before age 60.

Q: Hormone replacement therapy (HRT) is protective against which of the following?

Hip fracture. **Explanation:** **1. Why Hip Fracture is Correct:** Estrogen plays a critical role in maintaining bone mineral density (BMD) by inhibiting osteoclast activity and reducing bone resorption. After menopause, the decline in estrogen leads to rapid bone loss. Hormone Replacement Therapy (HRT) effectively halts this process and has been clinically proven to reduce the risk of osteoporotic fractures, including **hip, vertebral, and wrist fractures**. According to the Women’s Health Initiative (WHI) study, HRT is one of the most effective treatments for preventing postmenopausal bone loss. **2. Why the Other Options are Incorrect:** * **Breast Cancer:** Long-term use of combined HRT (Estrogen + Progesterone) is associated with an **increased risk** of breast cancer. Estrogen-only therapy (in women without a uterus) has a more neutral or slightly lower risk profile, but HRT is never considered "protective" against it. * **Deep Vein Thrombosis (DVT):** Oral HRT increases the synthesis of clotting factors in the liver (first-pass metabolism), leading to a **higher risk** of venous thromboembolism (VTE) and DVT. * **Myocardial Infarction (MI):** While HRT may have a cardioprotective effect if started early (the "Timing Hypothesis"), the WHI study showed that starting combined HRT in older postmenopausal women actually **increases** the risk of coronary heart disease and stroke. **NEET-PG High-Yield Pearls:** * **Gold Standard Indication:** The primary indication for HRT is the management of moderate-to-severe **vasomotor symptoms** (hot flashes). * **The "Window of Opportunity":** HRT is safest when started within 10 years of menopause or before age 60. * **Uterine Status:** Always add Progesterone to Estrogen if the patient has an intact uterus to prevent **Endometrial Carcinoma**. * **Colorectal Cancer:** Interestingly, combined HRT is also associated with a **decreased risk** of colorectal cancer.

Q: A 33-year-old female presents with a 6-month history of amenorrhea. Biochemical investigations showed increased FSH and decreased estradiol. What is the most likely diagnosis?

Premature menopause. ### Explanation **Correct Answer: C. Premature menopause** The clinical presentation of a woman under 40 years of age with amenorrhea for >4 months, associated with **elevated FSH (>40 IU/L)** and **low estradiol**, is diagnostic of **Premature Ovarian Failure (POF)**, also known as **Premature Menopause**. The underlying pathophysiology is the depletion of the ovarian follicle pool or follicular resistance. Due to the lack of negative feedback from estrogen and inhibin-B (produced by follicles), the pituitary gland secretes excessively high levels of Follicle Stimulating Hormone (FSH) in an attempt to stimulate the ovaries. **Analysis of Incorrect Options:** * **A. PCOD:** Characterized by hyperandrogenism and polycystic morphology on ultrasound. Hormonally, it typically shows an **increased LH:FSH ratio (2:1 or 3:1)**, not elevated FSH. * **B. Hyperprolactinemia:** High prolactin levels inhibit GnRH pulsatility, leading to low or normal FSH and LH (**Hypogonadotropic Hypogonadism**). * **D. Ectopic Pregnancy:** Presents with amenorrhea and abdominal pain. The biochemical marker is **elevated β-hCG**, not FSH. **High-Yield Clinical Pearls for NEET-PG:** * **Definition:** Menopause occurring before the age of **40 years**. * **Gold Standard Diagnostic:** Two readings of serum FSH >40 IU/L (some guidelines use >25-30 IU/L) taken at least 4 weeks apart. * **Most Common Karyotype Abnormality:** Turner Syndrome (45,XO) or Mosaicism (45,X/46,XX). * **Fragile X Premutation:** The most common known genetic cause of "sporadic" premature menopause. * **Management:** Hormone Replacement Therapy (HRT) is mandatory until the age of natural menopause (approx. 50 years) to prevent osteoporosis and cardiovascular disease.

Q: Identify the condition that is least likely to cause postmenopausal bleeding?

Ovarian follicular cyst. ***Ovarian follicular cyst*** * **Follicular cysts** result from failed ovulation and require active high **FSH** stimulation, making them generally rare or transient findings in **postmenopausal** women due to ovarian senescence. * Unlike other estrogen-producing tumors, simple follicular cysts usually do not produce sufficient sustained **estrogen** levels to pathologically stimulate the endometrium and cause bleeding in the postmenopausal period. *Endometrial CA* * **Endometrial carcinoma** is the most common cause of postmenopausal bleeding, accounting for 10-15% of cases, and must be ruled out in every patient presenting with this symptom. * Bleeding results from the erosion, ulceration, and breakdown of the friable, neoplastic tissue lining the **endometrium**. *Granulosa cell tumor* * This is a classic example of an **estrogen-producing ovarian tumor** (a sex cord-stromal tumor). * The chronic, unopposed **estrogen** stimulation causes proliferation of the endometrium, leading to subsequent **endometrial hyperplasia** or cancer, resulting in bleeding. *Genital tract trauma* * Trauma, including minor injuries, is a significant cause of postmenopausal bleeding due to underlying **vaginal and cervical atrophy**. * Postmenopausal tissue is thin, lacks pliancy, and is fragile, making it susceptible to bleeding even from minor trauma during examination, intercourse, or other physical contact.

Q: A 60-year-old woman presents with postmenopausal bleeding per vaginum. Both per vaginum and per speculum examination reveal no abnormality, and the Pap smear is normal. What will be the most appropriate management?

Measure endometrial thickness with ultrasound. ***Measure endometrial thickness with ultrasound*** - **Postmenopausal bleeding (PMB)** is a significant symptom that requires thorough evaluation to rule out **endometrial hyperplasia** or **carcinoma**, even with normal clinical exams and Pap smear. - Measuring **endometrial thickness with transvaginal ultrasound (TVS)** is the **first-line investigation** for PMB to assess for abnormalities. - **Endometrial thickness >4-5mm** warrants further evaluation with **endometrial biopsy** to rule out malignancy. - This is a non-invasive, cost-effective screening tool with high sensitivity for detecting endometrial pathology. *Keep her under observation* - This approach is inappropriate for PMB, as **10-15% of cases** can indicate underlying serious pathology like **endometrial cancer**. - **Prompt investigation** is necessary to ensure timely diagnosis and treatment. - Observation without investigation can lead to dangerous delays in cancer diagnosis. *Administer haemostatics* - Administering haemostatics addresses the symptom (bleeding) but does not identify or treat the underlying cause, which could be malignant. - This would delay crucial diagnostic evaluation and potentially worsen the prognosis if a **malignant condition** is present. - **PMB always requires investigation**, not symptomatic treatment alone. *Hysterectomy* - Hysterectomy is an invasive surgical procedure and is considered a definitive treatment, not a diagnostic step in this initial presentation. - It would only be contemplated after a definitive diagnosis of a serious condition, such as **endometrial cancer**, is made via less invasive means (e.g., endometrial biopsy). - Diagnostic workup should proceed stepwise: **TVS → endometrial biopsy → treatment decision**.

Question 1

Regarding vasomotor symptoms seen with menopause, all are true except?

Accepted Answer

Hot flush affects typically trunk and limbs.

Answer

Most common symptom of menopause.

Answer

Fall in circulating oestrogen levels disrupts the body's thermostat.

Answer

70 percent of women experience vasomotor symptoms at menopause.

Question 2

Which of the following is NOT true about the menopausal transition?

Accepted Answer

Increase in inhibin B

Answer

Increase in FSH

Answer

Decrease in estrogen

Answer

Decrease in AMH

Question 3

What is an absolute contraindication to hormone replacement therapy?

Accepted Answer

Otosclerosis

Answer

Osteoporosis

Answer

Colon cancer

Answer

Premature menopause

Question 4

All of the following agents are used in the treatment of hot flashes, EXCEPT?

Accepted Answer

Tamoxifen

Answer

Venlafaxine

Answer

Gabapentin

Answer

Paroxetine

Question 5

Which of the following is NOT a contraindication for estrogen therapy?

Accepted Answer

Hypertension

Answer

Uterine cancer

Answer

Breast cancer

Answer

Previous history of thromboembolism

Question 6

Hormone replacement therapy (HRT) is protective against which of the following?

Accepted Answer

Hip fracture

Answer

Breast cancer

Answer

Deep vein thrombosis (DVT)

Answer

Myocardial infarction (MI)

Question 7

A 33-year-old female presents with a 6-month history of amenorrhea. Biochemical investigations showed increased FSH and decreased estradiol. What is the most likely diagnosis?

Accepted Answer

Premature menopause

Answer

Polycystic Ovarian Disease (PCOD)

Answer

Hyperprolactinemia

Answer

Ectopic pregnancy

Question 8

Which among the following is the treatment of choice for senile vaginitis?

Accepted Answer

Estrogen cream

Answer

Oral pills

Answer

Nystatin locally

Answer

Ketoconazole

Question 9

Identify the condition that is least likely to cause postmenopausal bleeding?

Accepted Answer

Ovarian follicular cyst

Answer

Genital tract trauma

Answer

Endometrial CA

Answer

Granulosa cell tumor

Question 10

A 60-year-old woman presents with postmenopausal bleeding per vaginum. Both per vaginum and per speculum examination reveal no abnormality, and the Pap smear is normal. What will be the most appropriate management?

Accepted Answer

Measure endometrial thickness with ultrasound

Answer

Keep her under observation

Answer

Administer haemostatics

Answer

Hysterectomy

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?